2–Year Outcomes of the Treatment of Defects from Bone Marrow Lesions with Subchondroplasty[1]

Zimmer Biomet Summary of Published Article

66 Procedures Performed by Steven B. Cohen, MD, of The Rothman Institute, Philadelphia

Bone marrow lesions (BML) are MRI-visible reactions to stress injuries or fractures of the subchondral bone.[1] These defects occur when bone remodeling fails due to ongoing or increased stress and/or reduced healing capacity in the region.[2] Patients with BML defects typically have substantial chronic, aching pain, primarily on weight-bearing, and may have a worsening prognosis when left untreated.[3,4]

In patients with BML defects of the knee, current treatment guidelines recommend an initial course of conservative care, which may improve symptoms and delay further treatment.[5,6] Patients with these defects, however, are likely to progress to requiring total knee replacement (TKR) or osteotomy,[6,7] with an incidence reported in one study as 9 times more likely than patients without marrow involvement.[6] Although generally successful, TKR is associated with prolonged recovery and ongoing functional limitations. Less invasive treatment options with more rapid recovery would be desirable, especially for younger or more-active patients.

A promising treatment for subchondral bone defects associated with BML is Subchondroplasty® (SCP®), developed by Peter Sharkey, MD and Charles Leinberry, MD.[8] The SCP Procedure fi lls cancellous bone defects with AccuFill®, an injectable, flowable, engineered calcium phosphate bone substitute.[8,9,10] AccuFill crystallizes and hardens in an endothermic reaction at 37° C to form a nanocrystalline, macroporous scaffold in the subchondral bone, while also promoting cell-mediated remodeling.

Methods

Consecutive patients treated with SCP between May 2008 and May 2012 were contacted at least 2 years following SCP to determine post-operative state. Patients were evaluated for pain (VAS score) and length of delay to TKR. 2-year status was captured for 60 of 66 patients (91%).

Patient Demographics

- BML on MRI determined to be primary driver of patient symptoms
  - Pain isolated to compartment with BML
- Advanced DJD in compartment with BML, Mid-stage DJD in other 2 compartments
- All patients had been scheduled for TKR
- Non-responsive to other conservative or minimally-invasive therapy

	Age	Height	Weight (lbs)	BMI	Alignment	Symptom Length (months)	ICRS Grade in Treated Compartment
Min	33	5'0"	115	20.3	-10° Valgus	2	0
Avg	55.9	5'7"	195	30.1	1.9° Varus	22.4	3.6
Max	76	6'2"	350	53.2	8° Varus	180	4

Summary of Results

- Substantial, consistent reduction in pain
- 70% of patients delayed TKR at least 2 years
- Reduced rehabilitation time when compared to TKR

Summary of Results

1) SCP can help a patient delay a total knee replacement:

70% of patients who were scheduled to receive TKR were able to delay arthroplasty by at least 2 years.



2) SCP provided significant pain relief:

Pain improved by > 4 points.



3) SCP reduced rehabilitation and recovery as compared to TKR

Study postoperative protocol:

- Strict pain management 48-72 hours postop
- Weight bearing as tolerated with crutches as needed
- Standard post-arthroscopy PT regimen
- Return to Work and Activity as tolerated

Discussion

- SCP was offered as a targeted treatment of BML defect, as an alternative to total knee replacement
- Patients demonstrated and maintained a strong response to SCP treatment
- Reduced rehabilitation and recovery time when compared to TKR
- SCP demonstrated efficacy in a population with advanced DJD

References

1. Eriksen EF, Ringe JD. Bone marrow lesions: a universal bone response to injury? Rheumatol Int. 2012;32(3):575-584.
2. Roemer FW, Neogi T, Nevitt MC, *et al.* Subchondral bone marrow lesions are highly associated with, and predict subchondral bone attrition longitudinally: the MOST study. Osteoarthritis Cartilage. 2010;18(1):47-53.
3. Lo GH, Hunter DJ, Zhang Y, *et al.* Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum. 2005;52(9):2814-2821.
4. Felson DT, Chaisson CE, Hill CL,*et al.* The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med. 2001;134(7):541-549.
5. Jevsevar DS, Brown GA, Jones DL, *et al.* The American Academy of Orthopaedic Surgeons evidence-based guideline on: treatment of osteoarthritis of the knee, 2nd edition. J Bone Joint Surg Am. 2013;95(20):1885-1886.
6. Scher C, Craig J, Nelson F. Bone marrow edema in the knee in osteoarthrosis and association with total knee arthroplasty within a three-year follow-up. Skeletal Radiol. 2008;37(7):609-617.
7. Tanamas SK, Wluka AE, Pelletier JP, *et al.* Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. Rheumatology (Oxford). 2010;49(12):2413-2419.
8. Sharkey PF, Cohen SB, Leinberry CF, Parvizi J. Subchondral bone marrow lesions associated with knee osteoarthritis. Am J Orthop (Belle Mead NJ). 2012;41(9):413-417.
9. Cohen SB, Sharkey PF. Surgical Treatment of Osteoarthritis Pain Related to Subchondral Bone Defects or Bone Marrow Lesions: Subchondroplasty. Techniques in Knee Surgery. 2012;11(4):170-175. Available at: http://accellorthopedics.com/wp-content/uploads/2013/01/Cohen-2012-Knee-Creations.pdf.
10. Farr J,II, Cohen SB. Expanding Applications of the Subchondroplasty Procedure for the Treatment of Bone Marrow Lesions Observed on Magnetic Resonance Imaging. Operative Techniques in Sports Medicine. ;21(2):138-143. Available at: http://www.optechsportsmed.com/article/S1060-1872(13)00029-4/abstract.

AccuPort® Delivery Cannula and AccuMix® Mixing System are Manufactured by: Zimmer Knee Creations, 56 East Bell Drive, P.O.Box. 587, Warsaw, IN 46581 US. AccuFill® BSM is Manufactured by: ETEX Corporation, 55 Messina Drive, Braintree, MA 02184, USA.

For indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.

Legal Manufacturer
Zimmer Knee Creations
56 East Bell Drive
P.O. Box 587
Warsaw, IN 46581
USA

Legal Manufacturer
AccuFill BSM Manufactured By:
Etex Corporation
55 Messina Drive,
Braintree, MA 02184
USA

ZIMMER BIOMET

3881.2-US-en-Issue Date 2023-06

www.zimmerbiomet.com